Key Highlights
- Shares traded at $1.57 in today's intraday trading, up 0.64%, in penny-stock territory.
- Second-quarter 2026 results showed a net loss of about $4.2 million, with the company reiterating its 2026 Revenue guidance of roughly $18.5 million.
- BARDA-related government revenue declined during the quarter and cash burn widened.
- Spectral AI's lead technology, DeepView, uses AI to help clinicians assess burn and wound severity.
This penny stock, Spectral AI (NASDAQ:MDAI), is a medical-technology company developing artificial-intelligence-based predictive diagnostics, with its lead technology, DeepView, designed to help clinicians assess the severity of burns and wounds. Shares traded at $1.57 in today's intraday trading, up 0.64%.
Much of its funding has come from U.S. government sources such as BARDA, so its results depend on government contract revenue, progress toward regulatory clearance and commercialization of DeepView, and its ability to fund operations, making it a speculative, pre-commercial medical-technology company.
Latest Developments
In its second-quarter 2026 results, Spectral AI reported a net loss of about $4.2 million and reiterated its 2026 revenue guidance of roughly $18.5 million, while noting that BARDA-related revenue declined and cash burn widened. Investors should verify the latest revenue and its sources, the net loss and cash burn, the cash position, and regulatory progress and timelines for DeepView directly from SEC filings, recognizing that revenue tied to government funding can be lumpy.
Financial and Business Position
As a pre-commercial medical-technology company, Spectral AI's financial position is defined by its government-contract revenue, its ongoing losses and cash burn, and its cash, which funds its operations and development. Investors should focus on revenue and its sources, the net loss and cash burn, the cash runway, and regulatory progress and timelines for DeepView.
Stock-Market Context
MDAI shares traded at $1.57 in today's intraday trading, up 0.64%, keeping the stock in penny territory. The stock is a speculative small-cap medical-technology company whose shares are volatile and sensitive to regulatory news, government-funding trends, and cash burn.
What Investors Should Watch
Watch revenue and its sources, the net loss and cash burn, the cash runway, regulatory progress and timelines for DeepView, and any Capital raises. Regulatory clearance and progress toward commercialization of DeepView, backed by adequate funding, would favor the opportunity interpretation, while regulatory setbacks, declining government funding, or a widening cash burn would signal more risk.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...